News

Empresa emergente descobre nova forma de tratar autismo

Stalicla, uma startup genebrina, recorre a algoritmos para definir perfil biológico de cada grupo de autistas e, assim, identificar fármacos mais eficazes. O ensaio clínico do primeiro pacote terapêutico da empresa aguarda luz verde da agência reguladora de medicamentos dos Estados Unidos.

Read more

Lynn Durham joins expert panel at SACHS 12th European Life Sciences CEO Forum in Zurich

STALICLA SA’s CEO Lynn Durham joined a panel of leading industry experts at the SACHS European Life Sciences CEO Forum on February 25th-26th, 2019 in Zurich, Switzerland. The ‘Neuroscience BD&L’ panel which Lynn was part of, took place at 11:20am Monday 25th.

Read more

STALICLA announces closure of CHF 10 million total for first tranche of series A

STALICLA is pleased to announce the successful closure of the 2018 tranche of its series A round for a total amount of CHF 10M committed by a consortium of private and Biotech experienced investors

Read more

STALICLA CEO, Lynn Durham presents STALICLA’s most recent biomarker data at the 2nd Annual Neuroscience Innovation Forum in San Francisco

STALICLA CEO, Lynn Durham presents STALICLA’s most recent biomarker data at the 2nd Annual Neuroscience Innovation Forum in San Francisco

Read more

Search for content on Stalicla...